Is ALANINE AMINOTRANSFERASE INCREASED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ALANINE AMINOTRANSFERASE INCREASED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 62 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ALANINE AMINOTRANSFERASE INCREASED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ALANINE AMINOTRANSFERASE INCREASED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ALANINE AMINOTRANSFERASE INCREASED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ALANINE AMINOTRANSFERASE INCREASED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ALANINE AMINOTRANSFERASE INCREASED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ALANINE AMINOTRANSFERASE INCREASED: 62
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ALANINE AMINOTRANSFERASE INCREASED is a reported side effect: 1.8624%

FDA reports of any drug causing ALANINE AMINOTRANSFERASE INCREASED : 33840
Average percentage for all medicated patients where ALANINE AMINOTRANSFERASE INCREASED is reported as a complication: 0.2121%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ALANINE AMINOTRANSFERASE INCREASED:

ASPIRIN (2196 patients)
TRACLEER (1770 patients)
PREDNISOLONE (1443 patients)
CYMBALTA (1390 patients)
LIPITOR (1377 patients)
ACETAMINOPHEN (1376 patients)
LASIX (1146 patients)
METHOTREXATE (1121 patients)
OMEPRAZOLE (1016 patients)
ALLOPURINOL (894 patients)
FUROSEMIDE (874 patients)
ZYPREXA (862 patients)
EXJADE (845 patients)
SIMVASTATIN (815 patients)
ARAVA (755 patients)
NORVASC (713 patients)
CLOZARIL (704 patients)
KETEK (684 patients)
REMICADE (682 patients)
IBUPROFEN (672 patients)
LEVOTHYROXINE SODIUM (665 patients)
FOLIC ACID (658 patients)
SEROQUEL (656 patients)
PREDNISONE (650 patients)
TEGRETOL (618 patients)
LANSOPRAZOLE (602 patients)
FAMOTIDINE (598 patients)
ATENOLOL (598 patients)
LORAZEPAM (594 patients)
DIOVAN (579 patients)
ZOCOR (579 patients)
GLEEVEC (578 patients)
PREDONINE (578 patients)
LISINOPRIL (561 patients)
LAMICTAL (559 patients)
CYCLOPHOSPHAMIDE (554 patients)
ACCUTANE (551 patients)
CRESTOR (550 patients)
NEXIUM (549 patients)
ZOMETA (542 patients)
VOLTAREN (531 patients)
COUMADIN (526 patients)
DEXAMETHASONE (520 patients)
SYNTHROID (505 patients)
METFORMIN HCL (475 patients)
POTASSIUM CHLORIDE (471 patients)
RISPERDAL (467 patients)
WARFARIN SODIUM (465 patients)
AMLODIPINE (461 patients)
BACTRIM (452 patients)
LAMISIL (452 patients)
NEXAVAR (444 patients)
DIGOXIN (440 patients)
NEORAL (431 patients)
NEURONTIN (428 patients)
ENBREL (428 patients)
ACYCLOVIR (421 patients)
DECADRON (419 patients)
PLAVIX (419 patients)
LAMIVUDINE (417 patients)
SPIRONOLACTONE (416 patients)
CLONAZEPAM (414 patients)
CYCLOSPORINE (413 patients)
VIOXX (411 patients)
HYDROCHLOROTHIAZIDE (403 patients)
FOSAMAX (403 patients)
VANCOMYCIN (400 patients)
FLUCONAZOLE (397 patients)
PAXIL (395 patients)
MAGNESIUM OXIDE (389 patients)
CYTARABINE (389 patients)
MUCOSTA (386 patients)
AUGMENTIN '125' (382 patients)
LOXONIN (379 patients)
ZOLOFT (377 patients)
RAMIPRIL (376 patients)
AMBIEN (373 patients)
ZETIA (372 patients)
XANAX (371 patients)
CIPROFLOXACIN (370 patients)
STRATTERA (364 patients)
OXYCONTIN (350 patients)
DEPAKENE (350 patients)
LYRICA (349 patients)
ALDACTONE (349 patients)
AVONEX (348 patients)
CLARITHROMYCIN (345 patients)
MORPHINE (342 patients)
PREDNISONE TAB (339 patients)
ALBUTEROL (335 patients)
LOVENOX (335 patients)
RIBAVIRIN (333 patients)
REVLIMID (333 patients)
CARBOPLATIN (327 patients)
PARACETAMOL (320 patients)
ZANTAC (319 patients)
ZOFRAN (317 patients)
PROTONIX (316 patients)
ATIVAN (315 patients)
AMARYL (305 patients)
CARBAMAZEPINE (303 patients)
LEVOFLOXACIN (299 patients)
SELBEX (294 patients)
CLOZAPINE (290 patients)
HUMIRA (287 patients)
OXYCODONE HCL (286 patients)
VICODIN (284 patients)
INSULIN (282 patients)
SOLU-MEDROL (282 patients)
LEXAPRO (277 patients)
MIRTAZAPINE (276 patients)
PACLITAXEL (275 patients)
URSO 250 (272 patients)
DIAZEPAM (272 patients)
VELCADE (272 patients)
AMOXICILLIN (270 patients)
ATORVASTATIN CALCIUM (269 patients)
RHEUMATREX (268 patients)
CISPLATIN (268 patients)
DIFLUCAN (265 patients)
PEG-INTRON (264 patients)
EFFEXOR (262 patients)
VITAMIN D (260 patients)
PEGASYS (259 patients)
IRESSA (259 patients)
PREVACID (258 patients)
GABAPENTIN (258 patients)
CELEBREX (257 patients)
REBIF (256 patients)
FENTANYL (256 patients)
PROGRAF (255 patients)
REBETOL (254 patients)
TRAMADOL HCL (252 patients)
TOPROL-XL (250 patients)
PRILOSEC (250 patients)
ENALAPRIL MALEATE (250 patients)
LANTUS (249 patients)
HEPARIN (246 patients)
ALLEGRA (244 patients)
NORVIR (244 patients)
AMLODIPINE BESYLATE (243 patients)
KEPPRA (242 patients)
SINGULAIR (241 patients)
RANITIDINE (241 patients)
GASTER (240 patients)
VALPROATE SODIUM (237 patients)
MULTI-VITAMINS (237 patients)
AVASTIN (235 patients)
ONDANSETRON (235 patients)
RITONAVIR (235 patients)
PANTOPRAZOLE SODIUM (233 patients)
ZYRTEC (230 patients)
METHYLPREDNISOLONE (229 patients)
ACTOS (229 patients)
METOPROLOL TARTRATE (227 patients)
VIREAD (225 patients)
MYLOTARG (225 patients)
VINCRISTINE (225 patients)
KALETRA (225 patients)
ALPRAZOLAM (223 patients)
FLUOROURACIL (222 patients)
VALTREX (218 patients)
MULTI-VITAMIN (218 patients)
TYSABRI (214 patients)
LAPATINIB (214 patients)
MORPHINE SULFATE (213 patients)
ZIDOVUDINE (213 patients)
TYLENOL (212 patients)
ADVAIR DISKUS 100/50 (211 patients)
DOXORUBICIN HCL (211 patients)
DICLOFENAC SODIUM (210 patients)
ZOLPIDEM TARTRATE (210 patients)
METFORMIN (209 patients)
PEPCID (208 patients)
ACETYLSALICYLIC ACID SRT (208 patients)
ETOPOSIDE (205 patients)
CALCIUM (205 patients)
TRUVADA (204 patients)
DEPAS (204 patients)
PLATELETS (203 patients)
COMPAZINE (202 patients)
BISOPROLOL FUMARATE (201 patients)
PROZAC (200 patients)
EPIVIR (199 patients)
TRAZODONE HCL (198 patients)
CITALOPRAM HYDROBROMIDE (197 patients)
GILENYA (195 patients)
COMBIVIR (194 patients)
NIFEDIPINE (194 patients)
ISONIAZID (193 patients)
AMITRIPTYLINE HCL (192 patients)
TACROLIMUS (191 patients)
AMIODARONE HCL (190 patients)
OLANZAPINE (190 patients)
KYTRIL (189 patients)
CALCIUM CARBONATE (189 patients)
ABILIFY (189 patients)
PANTOPRAZOLE (188 patients)
METOCLOPRAMIDE (188 patients)
RISPERIDONE (187 patients)
METRONIDAZOLE (186 patients)
PERCOCET (186 patients)
TAKEPRON (185 patients)
GLUCOPHAGE (183 patients)
TRASTUZUMAB (183 patients)
FENOFIBRATE (182 patients)
MYCOPHENOLATE MOFETIL (182 patients)
ASCORBIC ACID (180 patients)
DEPAKOTE (180 patients)
ATARAX (180 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ALANINE AMINOTRANSFERASE INCREASED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.